Assessment on Treatments With Conventional Synthetic Disease-modifying Drugs Before Initiating Biologics in Patients With Rheumatoid Arthritis in Korea: A Population-based Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Min Jung | - |
dc.contributor.author | Park, Eun Hye | - |
dc.contributor.author | Shin, Anna | - |
dc.contributor.author | Ha, You-Jung | - |
dc.contributor.author | Lee, Yun Jong | - |
dc.contributor.author | Lee, Eun Bong | - |
dc.contributor.author | Baek, Han Joo | - |
dc.contributor.author | Kang, Eun Ha | - |
dc.date.accessioned | 2023-03-08T10:13:07Z | - |
dc.date.available | 2023-03-08T10:13:07Z | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 2093-940X | - |
dc.identifier.issn | 2233-4718 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/62135 | - |
dc.description.abstract | Objective: To assess pre-biologic treatments with conventional synthetic disease-modifying drugs (csDMARDs) prior to biologics initiation among patients with rheumatoid arthritis (RA). Methods: Using Korea National Health Insurance database, we examined pre-biologic treatments of RA patients on the following four items: whether 1) initial methotrexate (MTX) therapy was given, 2) MTX dose was escalated up to ≥15 mg/week within 1-year post-diagnosis, 3) prednisone-equivalent glucocorticoid was used at a dose of ≤7.5 mg/day, and 4) glucocorticoid was discontinued within 6 months of treatment. Multivariable logistic regressions identified predictors of items 2) and 4) fulfillment. Results: Among 6,986 biologics initiators with RA, 54.9% used MTX as the 1st csDMARD. Within 1-year post-diagnosis, 85.2% used MTX with half of them achieving a dose of ≥15 mg/week. The majority (75.2%) of patients used glucocorticoids initially and 64.5% were still on glucocorticoids at 6 months, mostly at a dose of ≤7.5 mg/day. csDMARD combination was observed in 85.7%. Item 2) fulfillment was associated with males, younger age, glucocorticoid, combination therapy, cyclo-oxygenase-2 inhibitors, and viral hepatitis. Item 4) fulfillment was associated with males, MTX dose of ≥15 mg/week, combination therapy, viral hepatitis, and hospitalizations. Conclusion: RA patients in Korea were predominantly treated with MTX-based csDMARD combination plus glucocorticoids before initiating biologics, without sufficient MTX dose escalation or glucocorticoid discontinuation. Items 2) and 4) fulfillments were associated with patient age and gender, concomitant treatments, and comorbidities. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한류마티스학회 | - |
dc.title | Assessment on Treatments With Conventional Synthetic Disease-modifying Drugs Before Initiating Biologics in Patients With Rheumatoid Arthritis in Korea: A Population-based Study | - |
dc.title.alternative | Assessment on Treatments With Conventional Synthetic Disease-modifying Drugs Before Initiating Biologics in Patients With Rheumatoid Arthritis in Korea: A Population-based Study | - |
dc.type | Article | - |
dc.identifier.doi | 10.4078/jrd.2022.29.2.79 | - |
dc.identifier.bibliographicCitation | 대한류마티스학회지, v.29, no.2, pp 79 - 88 | - |
dc.identifier.kciid | ART002827261 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000782477500005 | - |
dc.identifier.scopusid | 2-s2.0-85128842872 | - |
dc.citation.endPage | 88 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 79 | - |
dc.citation.title | 대한류마티스학회지 | - |
dc.citation.volume | 29 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | Disease-modifying anti-rheumatic drugs | - |
dc.subject.keywordAuthor | Methotrexate | - |
dc.subject.keywordAuthor | Glucocorticoids | - |
dc.subject.keywordAuthor | Combination therapy | - |
dc.subject.keywordPlus | ANTIRHEUMATIC DRUGS | - |
dc.subject.keywordPlus | EULAR RECOMMENDATIONS | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | PREDNISOLONE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | TACROLIMUS | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRENDS | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.